AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use

Vandana Singh
·1 min read

  • The FDA has accepted AstraZeneca Plc’s (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) combination regime for metastatic castration-resistant prostate cancer (mCRPC).

  • Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co Inc (NYSE: MRK).

  • The application covers Lynparza combined with abiraterone and prednisone or prednisolone.

  • Also Read: Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study.

  • Under the priority review status, the Prescription Drug User Fee Act date is anticipated during the fourth quarter of 2022.

  • The submission was based on results from the PROpel Phase 3 trial that showed that the Lynparza combo reduced the risk of disease progression or death by 34% versus abiraterone alone.

  • Median radiographic progression-free survival was 24.8 months for Lynparza plus abiraterone versus 16.6 for abiraterone alone.

  • Lynparza is approved in the U.S. for HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations) progressed following prior treatment with enzalutamide or abiraterone.

  • Price Action: AZN shares are down 0.27% at $66.63 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.